KEY TAKEAWAYS
- The study aimed to investigate MCL’s clinical and pathological features in the immunochemotherapy era for accurate PROs.
- Researchers noticed a marked improvement in the outcome of MCL pts over the past two decades and anticipate further enhancement through clinical management.
Patients (pts) with mantle cell lymphoma (MCL) manifest diverse clinical presentations and outcomes, yet the existing prognostic models lack efficacy in addressing the demands of contemporary multidisciplinary management. Julie M. Vose and her team aimed to delve into MCL’s clinical and pathological characteristics during the immunochemotherapy era, primarily focusing on enhancing prognostic models for more precise patient-related outcome (PRO) predictions.
They performed an inclusive analysis through the North American MCL Project, a collaborative effort involving 23 institutions across North America. The study incorporated 586 cases of MCL diagnosed between 2000 and 2012. A thorough retrospective examination was conducted, encompassing these cases’ clinicopathological features, treatment modalities, and outcomes. The methodological approach involved a comprehensive evaluation of baseline parameters to establish novel prognostic models, subsequently validated in an independent cohort of MCL cases.
In front-line strategies, hematopoietic stem cell transplantation emerged as the most influential factor impacting outcomes in both overall survival (OS, P < 0.0001) and progression-free survival (PFS, p < 0.0001). Notably, P53 positive expression was the most significant pathological parameter, correlating with inferior outcomes (P < 0.0001 for OS and P= 0.0021 for PFS). Based on the baseline risk factor profile, a set of prognostic models was developed, incorporating clinical, laboratory, and pathological parameters tailored for various applications. When tested in the validation cohort, these models exhibited robust predictive power for survival, demonstrating a stratification resembling the training cohort.
The study concluded that the outcome of MCL pts has significantly improved over the past two decades, with further enhancements anticipated through evolving clinical management. The innovative prognostic models developed in this study are valuable tools that guide the selection of more suitable treatment strategies for patients with MCL.
Source: https://pubmed.ncbi.nlm.nih.gov/38104096/
Vose JM, Fu K, Wang L,et al. (2023). “North American Mantle Cell Lymphoma Consortium. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium. J Hematol Oncol. 2023 Dec 16;16(1):122. doi: 10.1186/s13045-023-01520-7. PMID: 38104096; PMCID: PMC10725579.
